Beijing, Oct 17.- The Deputy Prime Minister of Cuba Ricardo Cabrisas stressed here today that the joint company Biotech Pharmaceutical Limited (PBL) is a symbol of scientific-technical cooperation between both countries.
According to diplomatic sources, the also Minister of Foreign Trade and Foreign Investment toured that place and learned details about the investigations being carried out there.
According to a publication on the social network
The day before, the vice prime minister began a visit to China during which he will co-chair the XXX Session of the Intergovernmental Commission.
According to a statement from the Caribbean Foreign Ministry, the Commission will strengthen ties between both nations, review and project the main topics of mutual interest, including those related to the scientific-technical area and bilateral cooperation.
Recently, the director of the BPL Company, Bai Xianhong, praised the biotechnological cooperation between China and Cuba, as well as its positive impact on the Asian giant.
In an exclusive interview with Prensa Latina, the director thanked the island's experts for their contributions in the approval process of the humanized monoclonal antibody Nimotuzumab for the treatment of pancreatic cancer.
This was the first product marketed by BPL and the first humanized monoclonal antibody in China since 2008, with very positive results in the fight against nasopharyngeal cancer.
Pancreatic tumors are one of the deadliest tumors in the world, difficult to diagnose early, most of them are already in an advanced stage when they are found, the methods to combat it are limited and the mortality rate is high, he explained.
Hence the importance of this Sino-Cuban medicine that can benefit more people and extend life expectancy, he added.
Yanet Borrego, deputy general director and representative of the Cuban vice presidency of BPL, recently told Prensa Latina that the decision of the national Medicines Administration endorses the results of years of work.
The top Chinese regulator referred to the good results of the injectable product in clinical studies, its effectiveness in inhibiting the growth of malignant cells and its widespread use since 1998 in Cuba and other nations around the world.
Likewise, he pointed out that this helps consolidate the presence of Cuban biotechnology products in the Asian giant and the aspiration to reach other places where there are also access opportunities. (Text and photo: PL)
